Apalutamid

Apalutamide is an oral medication used to treat prostate cancer. It belongs to a class of drugs known as androgen receptor inhibitors. These drugs work by blocking the effects of androgens, such as testosterone, which can stimulate the growth of prostate cancer cells.

Apalutamide is approved for the treatment of metastatic castration-resistant prostate cancer and non-metastatic castration-resistant prostate cancer. It is taken as a tablet by mouth, typically once daily. The effectiveness of apalutamide is measured by its ability to slow the progression of the cancer and improve survival rates.

Common side effects associated with apalutamide include fatigue, rash, nausea, diarrhea, and hot flashes. More serious side effects can occur, and patients should discuss potential risks and benefits with their healthcare provider. Apalutamide is metabolized in the liver and can interact with other medications.

Clinical trials have demonstrated the efficacy of apalutamide in improving outcomes for men with advanced prostate cancer. It is often used in combination with androgen deprivation therapy. The development of apalutamide represents an advancement in the treatment options available for prostate cancer patients.